METHOD FOR CONTROLLING BLOOD GLUCOSE LEVELS AND DIGESTION CYCLES

• US 20140296943A1
• Filed: 03/13/2014
• Published: 10/02/2014
• Est. Priority Date: 03/14/2013
• Status: Abandoned Application

• Current Assignee: BioLogical Illumination, LLC
• Original Assignee: BioLogical Illumination, LLC
• Inventors: Maxik, Fredric S., Bartine, David E., Soler, Robert R.
• Application Number:
  US14/208,370
• Publication Number:
  US 20140296943A1
• Time in Patent Office: Days
• US Class Current: 607/88
• CPC Class Codes: A61N 2005/0626 Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment
• CPC Class Codes: A61N 5/0618 Psychological treatment

Abstract

A method of affecting a physiological rhythm is provided. The method may include the steps of receiving an indication of a physiological condition of a patient, determining if the physiological condition is outside an expected status, receiving an indication of a physiological rhythm status of the patient, determining a physiological rhythm phase of the patient responsive to the indicated physiological rhythm status, determining a treatment light configured to affect at least one of an advance and delay physiological rhythm response in the patient, and causing the treatment light to be emitted onto the patient.

Claims

1. A method of affecting a physiological rhythm comprising the steps of:

receiving an indication of a physiological condition of a patient;

determining if the physiological condition is outside an expected status;

receiving an indication of a physiological rhythm status of the patient;

determining a physiological rhythm phase of the patient responsive to the indicated physiological rhythm status;

determining a treatment light configured to affect at least one of an advance and delay physiological rhythm response in the patient; and

causing the treatment light to be emitted onto the patient.

2. The method according to claim 1 wherein the step of receiving the indication of a physiological condition of a patient comprises receiving a measurement of a physiological substance of the patient.

3. The method according to claim 2 wherein the physiological substance is selected from the group consisting of blood glucose, fasting blood glucose, and insulin.

4. The method according to claim 1 wherein the physiological rhythm status is an indicator selected from the group consisting of body temperature, activity level, chryptochrome level, leptin level, melatonin level, blood glucose level, insulin level, and cortisol level.

5. The method according to claim 1 wherein the physiological rhythm is a circadian rhythm.

6. The method according to claim 1 wherein the physiological rhythm response comprises affecting a change in at least one of IGF-1 secretion rate, insulin breakdown rate, gluconeogenesis rate, glycogenolysis rate, and glycogenesis rate in the patient.

7. The method according to claim 1 wherein the step of determining if the physiological condition is outside an expected status comprises:

determining a time of day associated with the indication of a physiological condition;

determining an expected status associated with the determined time of day; and

comparing the expected status to the indication of a physiological condition.

8. The method according to claim 1 wherein the step of receiving an indication of a physiological rhythm status of the patient comprises receiving a signal from a device worn by the patient.

9. A method of affecting a blood glucose level in a patient comprising the steps of:

receiving a blood glucose level of a patient;

determining if the blood glucose level is outside a target range;

receiving an indication of a physiological rhythm status of the patient;

determining a physiological rhythm phase of the patient responsive to the indicated physiological rhythm status;

determining a treatment light configured to affect at least one of an advance and delay physiological rhythm response in the patient to thereby affect the blood glucose level of the patient; and

causing the treatment light to be emitted onto the patient.

10. The method according to claim 9 wherein the physiological rhythm status is an indicator selected from the group consisting of body temperature, activity level, chryptochrome level, leptin level, melatonin level, blood glucose level, insulin level, and cortisol level.

11. The method according to claim 9 wherein the physiological rhythm is a circadian rhythm.

12. The method according to claim 9 wherein the physiological rhythm response comprises at least one of affecting a change in IGF-1 secretion rate, insulin breakdown rate, gluconeogenesis rate, glycogenolysis rate, and glycogenesis rate in the patient.

13. The method according to claim 9 wherein the step of determining if the blood glucose level is outside a target range comprises:

determining a time of day associated with the received blood glucose level of the patient;

determining an expected blood glucose level associated with the determined time of day; and

comparing the expected blood glucose level to the received blood glucose level of the patient.

14. The method according to claim 9 wherein the step of receiving an indication of the physiological rhythm status of the patient comprises receiving a signal from a device worn by the patient.

15. The method according to claim 9 wherein, when the blood glucose level is determined to be above the target range, and when the physiological rhythm phase is determined to be one of a day phase, an evening phase, or a night phase, the treatment light is configured to affect a delay response.

16. The method according to claim 9 wherein, when the blood glucose level is determined to be above the target range, and when the physiological rhythm phase is determined to be a morning phase, the treatment light is configured to affect an advance response.

17. The method according to claim 9 wherein, when the blood glucose level is determined to be below the target range, and when the physiological rhythm phase is determined to be one of a day phase, an evening phase, or a night phase, the treatment light is configured to affect an advance response.

18. The method according to claim 9 wherein, when the blood glucose level is determined to be below the target range, and when the physiological rhythm phase is determined to be a morning phase, the treatment light is configured to affect a delay response.

19. A method of affecting a blood glucose level in a patient by controlling the emission of light onto the patient via use of a computerized device operatively coupled to a lighting device that is configured to emit the light, the method comprising the steps of:

receiving a first signal indicating a blood glucose level of a patient via a communication device associated with the computerized device;

determining a time of day associated with the received blood glucose level of the patient;

determining an expected blood glucose level associated with the determined time of day;

comparing the expected blood glucose level to the received blood glucose level of the patient;

receiving a second signal comprising an indication of a physiological rhythm status of the patient from a device worn by the patient, the indication of physiological rhythm status being at least one of body temperature and activity level via the communication device;

determining a physiological rhythm phase of the patient responsive to the indicated physiological rhythm status;

determining a treatment light configured to affect at least one of an advance and delay physiological rhythm response in the patient to thereby affect the blood glucose level of the patient; and

transmitting a third signal to the lighting device causing the treatment light to be emitted thereby.

20. The method according to claim 19 wherein the physiological rhythm response comprises affecting a change in at least one of IGF-1 secretion rate, insulin breakdown rate, gluconeogenesis rate, glycogenolysis rate, and glycogenesis rate in the patient.